Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Fenofibrate
Cat. No.:
OB0225LY-0492
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Fenofibrate is a selective PPARα agonist.
Synonym:
Procetofen; Lipanthyl; Lipantil; 49562-28-9; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate; Propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
CAS No.:
49562-28-9
Compound CID:
3339
Formula:
C20H21ClO4
Formula Weight:
360.83
Specification
Relative Density:
1.177 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Fenofibrate can be used in metabolic syndrome and cardiovascular disease research or play an important role in exploring the mechanisms of lipid metabolism.
Library Information
Targets:
Nuclear receptors; Cytochrome P450 enzymes
Receptors:
CYP2B6; CYP2C; CYP2C19; Cytochrome P450; PPARα
Pathways:
Autophagy; DNA damage/DNA repair; Metabolism
Plate Number:
AOCL-7
Plate Location:
d2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL; 152.43 mM
Ethanol Max Solubility:
36.1 mg/mL; 100 mM
ALogP:
5.111
HBA_Count:
4
HBD_Count:
0
Rotatable Bond:
7
